MedTrace Logo

Phenol or Laser: Best Minimally Invasive Treatment for Pilonidal Sinus?

NCT06721169 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 64

Last updated 2026-03-25

No results posted yet for this study

Summary

Pilonidal sinus disease is a common condition. There is still ongoing research on the ideal treatment. Pilonidal sinus disease is most common in men between the ages of 20 and 30. For patients with symptoms of pilonidal sinüs (pain, itching and discharge with soiling of underwear) that interfere with their normal daily life, several treatment options have emerged. A hairy body, thick skin, overweight, a deep gluteal cleft, lack of hygiene, sedentarism, repeated chafing and previous familial history are commonly admitted as predisposing factors.

There are various surgical and non-surgical methods for its treatment. Many different surgical techniques have been defined. None of these surgical techniques are defined as 'gold standard'.

For many years, wide excision and secondary healing was the standard approach for pilonidal sinus disease. However, when this method resulted in prolonged healing and restriction of regular activities, various reconstructive methods were developed to demonstrate the disadvantages of secondary healing.

A minimally invasive treatment modality for pilonidal sinüs dissease is excision of the sinus pit(s) followed by application of phenol to the sinus tract. Phenol is a sclerosing agent that destroys the epithelium and debris in the sinus, and is, thus, able to promote healing of the sinus.

Recently, advances in laser technology have made laser ablation of the sinus tract possible. The aim is to destroy and obliterate the sinus tracts with thermal energy produced by the laser probe.

The aim of this prospective observational study was to compare phenolization and laser ablation in the treatment of pilonidal sinus disease.

Conditions

  • Pilonidal Sinus Treatment
  • Pilonidal Sinus Disorder
  • Surgical Outcomes

Sponsors & Collaborators

  • Mersin University

    lead OTHER

Principal Investigators

  • Doğuş Parlak, PhD · Mersin University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-28
Primary Completion
2026-06-15
Completion
2026-07-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06721169 on ClinicalTrials.gov